相关实验视频

Updated: Jan 17, 2026

Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics

Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics

Published on: March 15, 2024

通过JAK2/STAT3途径对血管痴呆症中S100A8介导的铁死进行机械研究

XiaoYu Liu¹, XiuMin Zhao¹, BaiKe Zhu¹

¹Department of Neurology, Shandong Provincial Third Hospital, Shandong University, No.11, Wuyingshan Middle Road, Tianqiao District, Jinan City, 250031, Shandong Province, China.

Applied biochemistry and biotechnology

|January 15, 2026

概括

在血管痴呆症中,S100A8通过激活JAK2/STAT3通路来驱动铁. 抑制S100A8通过减少神经炎症和铁亡来显示血管痴呆的治疗潜力.

科学领域:

神经科学是一个神经科学.
细胞生物学细胞生物学
生物化学生物化学

背景情况:

血管痴呆症 (VaD) 是一种衰弱的神经系统疾病,其特点是认知能力下降.
铁,一种受调节的细胞死亡形式,在VaD的发病过程中起着重要作用.
在VaD中S100A8介导的铁化背后的精确分子机制仍然不完全理解.

研究的目的:

为了阐明S100结合蛋白A8 (S100A8) 在血管痴呆症 (VaD) 模型中的ferroptosis中的作用.
调查Janus激酶2/信号转换器和转录3 (JAK2/STAT3) 途径激活器在S100A8介导铁死中的参与.
探索S100A8作为VaD的潜在治疗点.

主要方法:

在小鼠中使用双侧动脉狭窄 (BCAS) 和在BV2微质细胞中使用氧气-葡萄糖剥夺 (OGD) 建立的VaD模型.
评估认知功能,神经病理,神经炎症和铁亡标志物 (Fe2+含量,ROS,线粒体膜潜力,脂质过氧化).
评估了JAK2/STAT3通路的激活,使用西方斑点和免疫光学.

主要成果:

在BCAS小鼠中,大脑的低 perfusion 在微质中调节了S100A8,与疾病进展相关.
在VaD模型中,S100A8抑制改善了认知缺陷,脑损伤,神经炎症和铁亡.
沉默S100A8缓解了BV2细胞中OGD诱导的炎症和铁亡,其作用由铁亡诱导剂/抑制剂调节.
S100A8抑制抑制了JAK2 / STAT3激活,而JAK2 / STAT3激活则逆转了S100A8沉默的保护作用.

结论:

在血管痴呆症中,S100A8是铁亡的关键媒介.
JAK2 / STAT3信号通路在S100A8诱导的铁亡中发挥了关键作用.
针对S100A8是一个有前途的治疗策略,用于血管痴呆.

关键词:

慢性大脑低 perfusion 的时间.铁性化 (ferroptosis) 是一种 JAK2/STAT3 3 的情况.在S100A8A8中使用.血管痴呆症是一种精神疾病.

相关概念视频

The JAK-STAT Signaling Pathway

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...

Mechanism of Angiogenesis

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...